Search Result

Results for "

CD3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD3 (36) 5-HT Receptor (6) Acetolactate Synthase (ALS) (1) Adenosine Receptor (1) Adrenergic Receptor (6) Androgen Receptor (3) Angiotensin Receptor (1) Antibiotic (10) Apoptosis (18) Aryl Hydrocarbon Receptor (1) Autophagy (21) Bacterial (11) Bcr-Abl (1) BCRP (1) c-Fms (1) c-Kit (2) Calcium Channel (2) CD19 (3) CD2 (1) CD20 (5) CD22 (1) CD28 (3) COX (9) CRISPR/Cas9 (1) CXCR (1) Cytochrome P450 (3) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (1) Dopamine Receptor (5) Drug Metabolite (6) EGFR (3) Elastase (1) Endogenous Metabolite (11) Estrogen Receptor/ERR (2) FAAH (1) Factor Xa (1) Ferroptosis (3) FGFR (3) FLT3 (2) Fungal (2) Glucocorticoid Receptor (1) GnRH Receptor (1) HCV (3) HCV Protease (1) Histamine Receptor (10) HIV (5) HIV Integrase (1) HIV Protease (1) HMG-CoA Reductase (HMGCR) (2) Imidazoline Receptor (1) Influenza Virus (2) Interleukin Related (2) Isotope-Labeled Compounds (129) Itk (1) Leukotriene Receptor (1) mAChR (1) MAP4K (1) MEK (1) Microtubule/Tubulin (2) Mitophagy (1) Neurokinin Receptor (1) NO Synthase (1) Notch (2) Nuclear Factor of activated T Cells (NFAT) (1) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) p38 MAPK (1) Parasite (4) PD-1/PD-L1 (5) PDGFR (5) Phosphatase (1) Phosphodiesterase (PDE) (1) Phospholipase (1) Potassium Channel (1) Progesterone Receptor (2) PROTACs (1) Proton Pump (2) Raf (3) Reactive Oxygen Species (1) RET (1) Reverse Transcriptase (1) SARS-CoV (6) Serotonin Transporter (1) Small Interfering RNA (siRNA) (4) Sodium Channel (2) Src (1) Thrombin (1) Thyroid Hormone Receptor (2) TNF Receptor (5) Topoisomerase (1) VD/VDR (1) VEGFR (7)
By Research Areas:	Cancer (81) Cardiovascular Disease (10) Endocrinology (19) Infection (25) Inflammation/Immunology (50) Metabolic Disease (17) Neurological Disease (26)
Click Chemistry:	Azide (2)
Oligonucleotides:	Pre-designed siRNA Sets (4) siRNAs (4)

217

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

152

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

*Anti-Mouse CD3* Antibody (17A2)** 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat.

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

Otelixizumab ChAglyCD3; TRX 4	CD3	Metabolic Disease
Otelixizumab (ChAglyCD3) is an anti-human *CD3* monoclonal antibody and can be used for the research of type 1 diabetes .

CD3D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CD3D Human Pre-designed siRNA Set A contains three designed siRNAs for CD3D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CD3E Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CD3E Human Pre-designed siRNA Set A contains three designed siRNAs for CD3E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CD3G Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CD3G Human Pre-designed siRNA Set A contains three designed siRNAs for CD3G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dafsolimab SPV-T3a	CD3	Infection
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and *CD3* and has anti-cancer activity for use in prostate cancer research .

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

Muromonab	CD3	Inflammation/Immunology Cancer
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

ABBV-383 TNB 383B; Etentamig	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
ABBV-383 (ABBV-383) is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. ABBV-383 can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and *CD3* of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

Maydispenoid A	CD28 CD3	Inflammation/Immunology
Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

Maydispenoid B	CD28 CD3	Inflammation/Immunology
Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and *CD3* epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

Solitomab AMG 110; MT110	CD3	Cancer
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the *CD3*. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human *CD3* monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

Immunosuppressant-1	Apoptosis	Inflammation/Immunology
Immunosuppressant-1 (Compound 31) inhibits anti-CD3/anti-CD28 co-stimulated T-cell proliferation. Immunosuppressant-1 has immunosuppressive activity, and induces apoptosis by activating caspase-3 and PARP in activated lymph node cells .

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) ^[3] .

BMS-243117	Src	Cancer
BMS-243117 is a potent, and selective benzothiazole based p56 ^Lck inhibitor with an IC₅₀ of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC₅₀ of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck .

UR-1505	Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related	Inflammation/Immunology
UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress *CD3/CD28* induced T cell proliferation, increase p27 ^KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .

ITK degrader 1	Itk	Cancer
ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; *DC₅₀*=3.6 nM in vivo in mice). ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC₅₀=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 also shows good plasma exposure levels .

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

Cat. No.	Product Name

HY-K0304

*Human CD3⁺ T Cells Negative Selection Kit*
MCE Human CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from human peripheral blood mononuclear cells (PBMC).

HY-K0306

*Mouse CD3⁺ T Cells Negative Selection Kit*
MCE Mouse CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

Cat. No.	Product Name	Target	Research Area

HY-P99124

*Anti-Mouse CD3* Antibody (17A2)** 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat.

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99038

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99211

Otelixizumab ChAglyCD3; TRX 4	CD3	Metabolic Disease
Otelixizumab (ChAglyCD3) is an anti-human *CD3* monoclonal antibody and can be used for the research of type 1 diabetes .

HY-P99539

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

HY-P99517

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and *CD3* and has anti-cancer activity for use in prostate cancer research .

HY-P99837

Dafsolimab SPV-T3a	CD3	Infection
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .

HY-P990864

*Anti-CD3* Antibody (OKT-3)**	Inhibitory Antibodies	Others
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a,?κ chimeric antibody, targeting to human *CD3. The recommend isotype control of Anti-CD3* Antibody (OKT-3): Mouse IgG2a kappa, Isotype Control (HY-P99978).

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P99152

Muromonab	CD3	Inflammation/Immunology Cancer
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P990785

ABBV-383 TNB 383B; Etentamig	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
ABBV-383 (ABBV-383) is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. ABBV-383 can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and *CD3* of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and *CD3* epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99592

Solitomab AMG 110; MT110	CD3	Cancer
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the *CD3*. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Inhibitory Antibodies	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human *CD3* antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human *CD3* monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) ^[3] .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99912

Emerfetamab AMG-673	Inhibitory Antibodies	Inflammation/Immunology
Emerfetamab is an anti-CD3E/CD33 monoclonal antibody .

HY-P99910

Eluvixtamab AMG-330	Inhibitory Antibodies	Inflammation/Immunology
Eluvixtamab is an anti-CD3E/CD33 monoclonal antibody .

HY-P990272

*Anti-Mouse CD3ε Antibody (KT3)*	Inhibitory Antibodies	Others
Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε.

HY-P990802

*Anti-Mouse CD3ε Antibody (145-2C11)*	Inhibitory Antibodies	Others
Anti-Mouse CD3ε Antibody (145-2C11) is a kind of Armenian hamster IgG1 in vivo mouse antibody, targeting to *CD3ε. The recommend isotype control of Anti-Mouse CD3*ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human *CD 3* receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P990698

Umizortamig	PD-1/PD-L1 EGFR	Inflammation/Immunology
Umizortamig is an anti-CD3E/EGFR/TNFRSF9/PD-L1/CD3G monoclonal antibody .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor	Inflammation/Immunology
Emfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody .

HY-P99948

Etevritamab AMG-596	EGFR	Inflammation/Immunology
Etevritamab is an anti-CD3E/EGFR monoclonal antibody .

HY-P990717

Brenetafusp	Inhibitory Antibodies	Inflammation/Immunology
Brenetafusp is an anti-CD3E/PRAME monoclonal antibody .

HY-P99916

Emirodatamab AMG-427	FLT3	Inflammation/Immunology
Emirodatamab is an anti-CD3E/FLT3 monoclonal antibody .

HY-P990688

Xaluritamig	Inhibitory Antibodies	Inflammation/Immunology
Xaluritamig is an anti-CD3E/STEAP1 monoclonal antibody .

HY-P990730

Cabotamig	Inhibitory Antibodies	Inflammation/Immunology
Cabotamig is an anti-CD3E/CDH17 monoclonal antibody .

HY-P990759

Rezetamig	CD22	Inflammation/Immunology
Rezetamig is an anti-CD3E/CD22 monoclonal antibody .

HY-P99868

Duvortuxizumab MGD 011	CD19	Others Cancer
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99523

Vepsitamab AMG 199	Classification of Application Fields Disease Research Fields Cancer	CD3
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Classification of Application Fields Disease Research Fields Cancer	Apoptosis
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99038

Odronextamab	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99392

Teclistamab	Classification of Application Fields Disease Research Fields Cancer	CD3
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99539

Ubamatamab REGN4018	Classification of Application Fields Disease Research Fields Cancer	CD3
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	Classification of Application Fields Disease Research Fields Cancer	CD3
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99521

Vibecotamab XmAb14045	Classification of Application Fields Disease Research Fields Cancer	CD3
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99152

Muromonab	Classification of Application Fields Disease Research Fields Cancer	CD3
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P99762

Obrindatamab MGD009	Classification of Application Fields Disease Research Fields Cancer	CD3
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99394

Talquetamab JNJ-64407564	Classification of Application Fields Disease Research Fields Cancer	CD3
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99623

Flotetuzumab MGD006; S80880	Classification of Application Fields Disease Research Fields Cancer	CD3
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-N10445

Maydispenoid A	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification Plants Salicaceae	CD28 CD3
Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

HY-N10446

Maydispenoid B	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	CD28 CD3
Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

HY-P9989

Linvoseltamab REGN5458	Classification of Application Fields Disease Research Fields Cancer	CD3 TNF Receptor
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and *CD3* epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-P99931

Epcoritamab GEN3013	Classification of Application Fields Disease Research Fields Cancer	CD3 CD20
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99592

Solitomab AMG 110; MT110	Classification of Application Fields Disease Research Fields Cancer	CD3
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99033

Mosunetuzumab BTCT-4465A	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99024

Glofitamab RO7082859	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Classification of Application Fields Disease Research Fields Cancer	Others
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human *CD3* antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P99776

Plamotamab XmAb-13676	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99562

Tidutamab XmAb-18087	Classification of Application Fields Disease Research Fields Cancer	CD3
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99011

Cibisatamab	Classification of Application Fields Disease Research Fields Cancer	CD3
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	Classification of Application Fields Disease Research Fields Cancer	CD3
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99814

Pavurutamab AMG-701	Classification of Application Fields Disease Research Fields Cancer	CD3
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) ^[3] .

HY-P99339

Tebentafusp IMCgp100	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related TNF Receptor
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99575

Tarlatamab AMG-757	Classification of Application Fields Disease Research Fields Cancer	Notch
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P9954

Catumaxomab	Classification of Application Fields Disease Research Fields Cancer	CD3
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human *CD 3* receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99868

Duvortuxizumab MGD 011	Classification of Application Fields Disease Research Fields Cancer	CD19
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .

HY-P99896

Runimotamab	Classification of Application Fields Disease Research Fields Cancer	Others
Runimotamab is an IgG1-κ humanized chimeric antibody targeting CD3E and HER2 .

HY-P99345

Dostarlimab TSR-042	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	Classification of Application Fields Disease Research Fields Cancer	CD19
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for *CD3E* on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia ^[3] .

HY-P99798

Pacanalotamab AMG 420; BI-836909	Classification of Application Fields Disease Research Fields Cancer	CD3
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and *CD3E*. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

Species:	Human (20) Rhesus Macaque (4) Mouse (6) Rat (1) Cynomolgus (12) Canine (2)
Tag:	His (18) Tag Free (2) Avi (5) Fc (27) Flag (5)
Source:	HEK293 (42) P. pastoris (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P76802

	CD3D-CD3E Heterodimer Protein, Rhesus Macaque (hFc) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Rhesus Macaque	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D-CD3E Heterodimer Protein, Rhesus Macaque is a recombinant protein dimer complex containing Rhesus Macaque-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with N-hFc.

HY-P72726

	CD3D-CD3E Heterodimer Protein, Human (HEK293, His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Human	HEK293
	CD3D Protein, an integral part of the TCR-CD3 complex on T-lymphocytes, plays a pivotal role in adaptive immunity. It transmits signals through CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D is essential for thymocyte differentiation, ensuring proper TCR-CD3 complex assembly and surface expression. Interacting with CD4 and CD8 coreceptors, CD3D establishes a functional link crucial for CD4 or CD8 T-cell activation and positive selection. Its multifaceted role orchestrates intricate T-cell responses. CD3D-CD3E Heterodimer Protein, Human (HEK293, His) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, His), has molecular weight of 16-30 kDa.

HY-P76237

	CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc) CD3E & CD3G; CD3 epsilon & CD3 gamma; CD3 epsilon/gamma	Rhesus Macaque	HEK293
	CD3E protein has predicted functions such as SH3 domain binding and protein heterodimerization, and plays a crucial role in nervous system development and cell adhesion. It is involved in T cell activation, cytokine production and signal transduction. CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc) is a recombinant protein dimer complex containing Rhesus Macaque-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc), has molecular weight of ~83 (40 + 43) KDa.

HY-P70434

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His), has molecular weight of 40-52 kDa.

HY-P72727

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His), has molecular weight of 40-60 kDa.

HY-P76220

	CD3 zeta/CD247 Protein, Human (His) T-cell surface glycoprotein CD3 zeta chain; CD247; CD3Z; T3Z; TCRZ	Human	E. coli
	CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (GST) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-GST labeled tag. The total length of CD3 zeta/CD247 Protein, Human (GST) is 113 a.a., with molecular weight of 28-43 KDa.

HY-P72728

	CD3 delta Protein, Cynomolgus (HEK293, His) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3 delta Protein, Cynomolgus (HEK293, His) is 84 a.a., with molecular weight of 20-35 kDa.

HY-P72899

	CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) T-cell surface glycoprotein CD3 epsilon chain; CD3E; T3E; CD3 epsilon	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-hFc, C-Flag, C-mFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc), has molecular weight of 42-47 kDa.

HY-P70091

	CD3 delta Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 delta chain/CD3d, Fc ; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 delta Protein, Cynomolgus (HEK293, Fc) is 84 a.a., with molecular weight of ~35.0 kDa.

HY-P71845

	CD3 gamma Protein, Cynomolgus (P.pastoris, His) CD3GT-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD antigen CD3g	Cynomolgus	P. pastoris
	CD3γ protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When the TCR is activated, CD3D, CD3E, CD3G, and CD3Z transmit TCR-mediated signals and activate downstream pathways. CD3 gamma Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived CD3 gamma protein, expressed by P. pastoris , with N-His labeled tag. The total length of CD3 gamma Protein, Cynomolgus (P.pastoris, His) is 91 a.a., with molecular weight of ~12.5 kDa.

HY-P77603

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc), has molecular weight of 58-62 kDa.

HY-P77604

	CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc), has molecular weight of 58-62 kDa.

HY-P77605

	CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Cynomolgus	HEK293
	CD3E/CD3 epsilon 1-27 peptide, crucial in the TCR-CD3 complex, transmits signals during T-cell activation. As APCs activate the TCR, CD3E, with ITAMs, undergoes LCK/FYN-mediated phosphorylation, initiating downstream signaling. Beyond signaling, CD3E contributes to T-cell development, forming CD3D/CD3E and CD3G/CD3E heterodimers. It regulates TCR-CD3 internalization through endocytosis sequences and interacts with CD6, NCK1, and NUMB, essential for internalization and degradation. The TCR-CD3 complex, including CD3D/CD3E and CD3G/CD3E heterodimers and CD3Z homodimers, demonstrates versatility in TCR assembly, allowing substitution of TCRalpha and TCRbeta with TCRgamma and TCRdelta. CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc), has molecular weight of 36.9 kDa(CD3E) & 36.5 kDa(CD3G), respectively.

HY-P77606

	CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Cynomolgus	HEK293
	CD3E/CD3 epsilon 1-27 peptide, crucial in the TCR-CD3 complex, transmits signals during T-cell activation. As APCs activate the TCR, CD3E, with ITAMs, undergoes LCK/FYN-mediated phosphorylation, initiating downstream signaling. Beyond signaling, CD3E contributes to T-cell development, forming CD3D/CD3E and CD3G/CD3E heterodimers. It regulates TCR-CD3 internalization through endocytosis sequences and interacts with CD6, NCK1, and NUMB, essential for internalization and degradation. The TCR-CD3 complex, including CD3D/CD3E and CD3G/CD3E heterodimers and CD3Z homodimers, demonstrates versatility in TCR assembly, allowing substitution of TCRalpha and TCRbeta with TCRgamma and TCRdelta. CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc), has molecular weight of 44-46 kDa.

HY-P77609

	CD3E-CD3G Heterodimer Protein, Human (HEK293, His) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-His labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, His), has molecular weight of 25-40 kDa.

HY-P77610

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc), has molecular weight of 40-53 kDa.

HY-P77611

	CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc), has molecular weight of 40-60 kDa.

HY-P77614

	CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Mouse	HEK293
	The CD3D protein is a crucial component of the TCR-CD3 complex on T-lymphocytes, essential for adaptive immune responses. Upon TCR activation by APCs, CD3D, along with CD3E, CD3G, and CD3Z, transmits signals through ITAMs, activating downstream pathways. CD3D is vital for proper thymocyte differentiation, ensuring intracellular TCR-CD3 complex assembly. Dysfunctional complexes impair thymocyte differentiation. CD3D also interacts with CD4 and CD8, linking TCR to coreceptors for CD4 or CD8 T-cell activation and positive selection. The CD3D contributes to the intricate network governing T-cell responses. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc) is a recombinant protein dimer complex containing mouse-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc), has molecular weight of 50-65 kDa.

HY-P700677

	CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, His) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3D Heterodimer Protein, Human (Biotinylated, HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3D Heterodimer protein, expressed by HEK293, with C-His labeled tag. CD3E-CD3D Heterodimer Protein, Human (Biotinylated, HEK293, His), has molecular weight of 25-40 kDa.

HY-P700678

	CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-His labeled tag. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His), has molecular weight of 25-40 kDa.

HY-P71723

	CD3 epsilon Protein, Mouse (P.pastoris, His) CD3eT-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD antigen CD3e	Mouse	P. pastoris
	The CD3 epsilon protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3E, together with CD3D, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3 epsilon Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived CD3 epsilon protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of CD3 epsilon Protein, Mouse (P.pastoris, His) is 86 a.a., with molecular weight of ~11.9 kDa.

HY-P77612

	CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi), has molecular weight of 48-60 kDa.

HY-P77613

	CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-Avi, C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi), has molecular weight of 48-55 kDa.

HY-P70506

	CD3 epsilon Protein, Human (HEK293, His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3 epsilon Protein, Human (HEK293, His) is 104 a.a., with molecular weight of ~18.0 kDa.

HY-P76788

	CD3 epsilon Protein, Rat (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rat	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 epsilon Protein, Rat (HEK293, Fc) is 80 a.a., with molecular weight of ~36.1 KDa.

HY-P77320

	CD3 epsilon Protein, Canine (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Canine	HEK293
	The CD3 ε protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When APC is activated, TCR signals transmitted by CD3D, CD3E, CD3G, and CD3Z initiate pathways through ITAM. CD3 epsilon Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76789

	CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76791

	CD3 epsilon Protein, Rhesus Macaque (HEK293, His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P70682

	CD3 epsilon Protein, Human (104a.a, HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is 104 a.a., with molecular weight of 40-50 kDa.

HY-P70824

	CD3 epsilon Protein, Human (27a.a, HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (27a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-mFc labeled tag. The total length of CD3 epsilon Protein, Human (27a.a, HEK293, Fc) is 27 a.a., with molecular weight of 32-40 kDa.

HY-P7879

	CD3D Protein, Human (HEK293, His) rHuT-cell surface glycoprotein CD3 delta chain/CD3D, His; T-Cell Surface Glycoprotein CD3 Delta Chain; T-Cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Human (HEK293, His) is the recombinant human-derived CD3D protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3D Protein, Human (HEK293, His) is 84 a.a., with molecular weight of 18-30 kDa.

HY-P78753

	CD3 gamma Protein, Human (HEK293, Fc) CD3G; CD3-GAMMA; IMD17; T3G; TCR gamma	Human	HEK293
	CD3 gamma, part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signaling and regulates surface expression. APC-induced TCR activation prompts CD3 gamma, along with CD3D, CD3E, and CD3Z, to transmit signals via ITAMs. Phosphorylation by LCK and FYN initiates downstream signaling. CD3 gamma's diL motif guides constitutive TCR cycling. In TCR-CD3 assembly, CD3 gamma shows versatility, forming heterodimers and trimers, highlighting its pivotal role in T-cell activation and receptor dynamics. CD3 gamma Protein, Human (HEK293, Fc) is the recombinant human-derived CD3 gamma protein, expressed by HEK293, with C-hFc labeled tag. The total length of CD3 gamma Protein, Human (HEK293, Fc) is 94 a.a., with molecular weight of 45-55 kDa.

HY-P78874

	CD3 epsilon Protein, Human (Biotinylated, HEK293, His) FLJ18683; T3E; TCRE; CD3E; CD3-epsilon	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P70090

	CD3 epsilon Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 epsilon chain/CD3E, Fc ; CD3 epsilon; CD3e antigen; CD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3-TCR complex); CD3e; CD3-epsilon; FLJ18683; T3E; T-cell antigen receptor complex, epsilon subunit of T3; T-cell surface antigen T3/Leu-4 epsilon chain	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293 , with C-Fc, C-hFc labeled tag. The total length of CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is 96 a.a., with molecular weight of 38-55 kDa.

HY-P78269

	CD3 epsilon Protein, Cynomolgus (HEK293, His) CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18	Cynomolgus	HEK293
	CD3E/CD3 epsilon 1-27 peptide, crucial in the TCR-CD3 complex, transmits signals during T-cell activation. As APCs activate the TCR, CD3E, with ITAMs, undergoes LCK/FYN-mediated phosphorylation, initiating downstream signaling. Beyond signaling, CD3E contributes to T-cell development, forming CD3D/CD3E and CD3G/CD3E heterodimers. It regulates TCR-CD3 internalization through endocytosis sequences and interacts with CD6, NCK1, and NUMB, essential for internalization and degradation. The TCR-CD3 complex, including CD3D/CD3E and CD3G/CD3E heterodimers and CD3Z homodimers, demonstrates versatility in TCR assembly, allowing substitution of TCRalpha and TCRbeta with TCRgamma and TCRdelta. CD3 epsilon Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293, with C-His labeled tag. The total length of CD3 epsilon Protein, Cynomolgus (HEK293, His) is 96 a.a., with molecular weight of 14-16 kDa.

HY-P75414

	CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc) AI504783 Protein; CD3 Protein; CD3epsilon Protein; T3e Protein	Mouse	HEK293
	CD3E protein has predicted functions such as SH3 domain binding and protein heterodimerization, and plays a crucial role in nervous system development and cell adhesion. It is involved in T cell activation, cytokine production and signal transduction. CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc) is a recombinant protein dimer complex containing mouse-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc), has molecular weight of ~38-40 kDa.

HY-P77607

	CD3 epsilon 1-27 peptide Protein, Cynomolgus (HEK293, Fc-Avi) CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon 1-27 peptide Protein, Cynomolgus (HEK293, Fc-Avi) is the recombinant cynomolgus-derived CD3E/CD3 epsilon 1-27 peptide protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P77608

	CD3 epsilon 1-27 peptide Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon 1-27 peptide Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) is the recombinant cynomolgus-derived CD3E/CD3 epsilon 1-27 peptide protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P78089

	CD3 epsilon 1-27 peptide Protein, Human (Biotinylated, HEK293, His-Avi) CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon 1-27 peptide Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD3 epsilon 1-27 peptide protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD3 epsilon 1-27 peptide Protein, Human (Biotinylated, HEK293, His-Avi) is 26 a.a., with molecular weight of 40-50 kDa.

HY-P76803

	CD3D Protein, Canine (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Delta Chain; T-Cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Canine	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75654

	CD3D Protein, Mouse (HEK293, Fc) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; T3d	Mouse	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3D Protein, Mouse (HEK293, Fc) is 105 a.a., with molecular weight of 48-65 kDa.

HY-P75416

	CD3D-CD3E Heterodimer Protein, Mouse (HEK293) CD3-DELTA Protein; IMD19 Protein; T3D Protein; CD3D; CD3E	Mouse	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D-CD3E Heterodimer Protein, Mouse (HEK293) is a recombinant protein dimer complex containing mouse-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with tag free. CD3D-CD3E Heterodimer Protein, Mouse (HEK293), has molecular weight of 45-50 kDa.

HY-P75415

	CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Flag-His) CD3-DELTA Protein; IMD19 Protein; T3D Protein; CD3D; CD3E	Mouse	HEK293
	The CD3D protein is a crucial component of the TCR-CD3 complex on T-lymphocytes, essential for adaptive immune responses. Upon TCR activation by APCs, CD3D, along with CD3E, CD3G, and CD3Z, transmits signals through ITAMs, activating downstream pathways. CD3D is vital for proper thymocyte differentiation, ensuring intracellular TCR-CD3 complex assembly. Dysfunctional complexes impair thymocyte differentiation. CD3D also interacts with CD4 and CD8, linking TCR to coreceptors for CD4 or CD8 T-cell activation and positive selection. The CD3D contributes to the intricate network governing T-cell responses. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Flag-His) is a recombinant protein dimer complex containing mouse-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with C-His, C-Flag labeled tag. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Flag-His), has molecular weight of ~20 & 22 kDa, respectively.

HY-P73498

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Flag-His) CD3-DELTA Protein; IMD19 Protein; T3D Protein; CD3D&CD3E Heterodimer Protein	Human	HEK293
	CD3D Protein, an integral part of the TCR-CD3 complex on T-lymphocytes, plays a pivotal role in adaptive immunity. It transmits signals through CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D is essential for thymocyte differentiation, ensuring proper TCR-CD3 complex assembly and surface expression. Interacting with CD4 and CD8 coreceptors, CD3D establishes a functional link crucial for CD4 or CD8 T-cell activation and positive selection. Its multifaceted role orchestrates intricate T-cell responses. CD3D-CD3E Heterodimer Protein, Human (HEK293, Flag-His) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with C-His, C-Flag labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, Flag-His), has molecular weight of ~20 & 22 & 26 kDa, respectively.

HY-P74301

	CD3D-CD3E Heterodimer Protein, Human (HEK293) T-cell receptor T3 delta chain; CD3D; T3D; CD3E; T3E	Human	HEK293
	CD3D Protein, an integral part of the TCR-CD3 complex on T-lymphocytes, plays a pivotal role in adaptive immunity. It transmits signals through CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D is essential for thymocyte differentiation, ensuring proper TCR-CD3 complex assembly and surface expression. Interacting with CD4 and CD8 coreceptors, CD3D establishes a functional link crucial for CD4 or CD8 T-cell activation and positive selection. Its multifaceted role orchestrates intricate T-cell responses. CD3D-CD3E Heterodimer Protein, Human (HEK293) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with tag free. CD3D-CD3E Heterodimer Protein, Human (HEK293), has molecular weight of 44-54 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80598

	CD3 epsilon Antibody CD3E; T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e	WB, IHC-P, IP	Human
	CD3 epsilon Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to CD3 epsilon. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human.

HY-P80600

	CD3D Antibody CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	CD3D Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 19 kDa, targeting to CD3D. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

HY-P80601

	CD3G Antibody CD3 gamma; CD3g; T3G	WB, IHC-P, IP	Human
	CD3G Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 20 kDa, targeting to CD3G. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human.

HY-P82680

	*Phospho-CD3* zeta (Tyr142) Antibody (YA2425)** CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247	WB, IP	Human
	Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2425), targeting Phospho-CD3 zeta (Tyr142), with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). Phospho-CD3 zeta (Tyr142) Antibody (YA2425) can be used for WB, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159123

KHK-6		Azide
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-17413S1

Zidovudine-13C,d3 Azidothymidine-¹³C,d₃; AZT-¹³C,d₃; ZDV-¹³C,d₃		Azide
Zidovudine- ¹³C,d₃ is the ¹³C- and deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency. Zidovudine-13C,d3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-RS02242

CD3D Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CD3D Human Pre-designed siRNA Set A contains three designed siRNAs for CD3D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02243

CD3E Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CD3E Human Pre-designed siRNA Set A contains three designed siRNAs for CD3E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02244

CD3G Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CD3G Human Pre-designed siRNA Set A contains three designed siRNAs for CD3G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01740

C2CD3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
C2CD3 Human Pre-designed siRNA Set A contains three designed siRNAs for C2CD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CD3

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products